Search Results

Icosavax, Inc. announced it has entered into a definitive agreement pursuant to which AstraZeneca, through an acquisition subsidiary, will initiate a tender offer to acquire all of Icosavax’s outstanding shares for a price of $15.00 per share in cash at closing, plus a non-tradable contingent value right to receive up to $5.00 in cash, payable upon achievement of specified regulatory and net sales milestones.

With the acquisition, AstraZeneca will gain access to Icosavax’s investigational combination vaccine IVX-A12, which is being developed for respiratory syncytial virus and human metapneumovirus in older adults.

AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc.

Icosavax, Inc. announced that the company will participate in and host one-on-one meetings at the Jefferies London Healthcare Conference, taking place from November 14-16, 2023 in London, UK.

Icosavax, Inc. (Nasdaq: ICVX) today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Icosavax, Inc. today announced that the company will participate in the Cantor Fitzgerald Global Healthcare Conference 2023, taking place from September 26-28, 2023.

Icosavax, Inc. announced positive topline interim results from its Phase 2 clinical trial of IVX-A12 against respiratory syncytial virus and human metapneumovirus in older adults.

Icosavax, Inc. today announced that the company will participate in and host one-on-one meetings at the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference, taking place from November 6-7, 2023 in New York City.

Icosavax, Inc. (Nasdaq: ICVX) today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Icosavax, Inc. today announced that the company will participate in and host one-on-one meetings at the following investor conferences.